Table 1, Submitted for Review - Empagliflozin (Jardiance)

Item	Description
Drug product	Empagliflozin (Jardiance), 10 mg^a or 25 mg, orally administered film-coated tablets
Indication	Indicated in adults as an adjunct to standard-of-care therapy for the treatment of chronic heart failure
Reimbursement request	For the treatment of heart failure in patients with NYHA class II, III, or IV. To be used as an adjunct to standard-of-care therapy
Health Canada approval status	Post-NOC
Health Canada review pathway	Priority review
NOC date	April 6, 2022
Sponsor	Boehringer Ingelheim Canada Ltd.

Item

Description

Drug product

Empagliflozin (Jardiance), 10 mg^a or 25 mg, orally administered film-coated tablets

Indication

Indicated in adults as an adjunct to standard-of-care therapy for the treatment of chronic heart failure

Reimbursement request

For the treatment of heart failure in patients with NYHA class II, III, or IV. To be used as an adjunct to standard-of-care therapy

Health Canada approval status

Post-NOC

Health Canada review pathway

Priority review

NOC date

April 6, 2022

Sponsor

Boehringer Ingelheim Canada Ltd.

From: Clinical Review

Empagliflozin (Jardiance): CADTH Reimbursement Review: Therapeutic area: Chronic heart failure [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Jan.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Table 1Submitted for Review